Table 1.
Comparison of the Baseline Characteristics of All Patients who Received Transarterial Chemoembolization (TACE) versus Best Supportive Care (BSC)
| Characteristics | BSC (n=26) | TACE (n=92) | P value |
|---|---|---|---|
| Male sex | 18 (69.2%) | 68 (73.9%) | 0.626 |
| Age (years): mean ± SD | 60.5 ± 11.5 | 58.6 ± 11.5 | 0.454 |
| BMI (kg/m2): mean ± SD | 21.68 ± 4.2 | 23.6 ± 4.5 | 0.053 |
| Etiology of chronic liver disease | |||
| Hepatitis B infection | 13 (50.0%) | 37 (40.2%) | 0.38 |
| Hepatitis C infection | 1 (3.8%) | 27 (29.2%) | 0.007 |
| Alcohol-related liver disease | 5 (19.2%) | 28 (30.4%) | 0.261 |
| Portal hypertension | 9 (34.6%) | 63 (68.5%) | <0.001 |
| Laboratory data | |||
| Hemoglobin (g/dL): mean ± SD | 10.5 ± 3.8 | 12.1 ±1.9 | 0.006 |
| Platelet median (x103/mL): median (IQR) | 216 (138 to 311) | 125 (80 to 218) | 0.143 |
| Serum creatinine (mg/dL): median (IQR) | 0.91 ± 0.29 | 0.88 ± 0.26 | 0.606 |
| Serum Albumin (g/dL): mean ± SD | 3.4 ± 0.6 | 3.5 ± 0.6 | 0.55 |
| Total bilirubin (mg/dL): median (IQR) | 1.2 (0.8 to 1.5) | 1.1 (0.7 to 1.9) | 0.765 |
| INR: mean ± SD | 1.0 ± 0.5 | 1.2 ± 0.2 | 0.001 |
| Alpha-fetoprotein (IU/mL): median (IQR) | 187.2 (2.0 to 3134.0) | 27.1 (7.9 to 832.7) | 0.548 |
| Alpha-fetoprotein > 200 (IU/mL) | 13 (50.0%) | 35 (38.0%) | 0.273 |
| ECOG score | 0.005 | ||
| 0 | 12 (46.2%) | 71 (77.2%) | |
| 1 | 14 (53.8%) | 21 (22.8%) | |
| Multinodular | 16 (61.5%) | 43 (46.7%) | 0.183 |
| Tumor > 5 cm | 23 (88.5%) | 64 (69.6%) | 0.053 |
| Median longest tumor size (cm): median (IQR) | 6.5 (4.0 to 12.8) | 4.8 (3.4 to 8.1) | 0.06 |
Data are expressed as number (%) unless otherwise specified; BMI, body mass index; SD, standard deviation; INR, international normalized ratio; IQR, interquartile range; ECOG, Eastern Cooperative Oncology Group